Q1 2020 13F Holders as of 3/31/2020
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
49.6M
-
Number of holders
-
116
-
Total 13F shares, excl. options
-
31.7M
-
Shares change
-
+4.72M
-
Total reported value, excl. options
-
$267M
-
Value change
-
+$39.2M
-
Put/Call ratio
-
1.25
-
Number of buys
-
54
-
Number of sells
-
-64
-
Price
-
$8.44
Significant Holders of PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) as of Q1 2020
160 filings reported holding PBYI - PUMA BIOTECHNOLOGY, INC. - Common Stock as of Q1 2020.
PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) has 116 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 31.7M shares
of 49.6M outstanding shares and own 63.87% of the company stock.
Largest 10 shareholders include STATE STREET CORP (3.54M shares), BlackRock Inc. (2.82M shares), EcoR1 Capital, LLC (2.54M shares), FRED ALGER MANAGEMENT, LLC (2.33M shares), Camber Capital Management LP (1.95M shares), MILLENNIUM MANAGEMENT LLC (1.95M shares), Palo Alto Investors LP (1.4M shares), RENAISSANCE TECHNOLOGIES LLC (1.09M shares), PRICE T ROWE ASSOCIATES INC /MD/ (1.04M shares), and FEDERATED HERMES, INC. (1.01M shares).
This table shows the top 116 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.